Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

Wolin E, Mita A, Mahipal A, Meyer T, Bendell J, Nemunaitis J, Munster PN, Paz-Ares L, Filvaroff EH, Li S, Hege K, de Haan H, Mita M.

PLoS One. 2019 Sep 17;14(9):e0221994. doi: 10.1371/journal.pone.0221994. eCollection 2019.

2.

Immunotherapy in Hepatocellular Carcinoma: Is There a Light at the End of the Tunnel?

Mahipal A, Tella SH, Kommalapati A, Lim A, Kim R.

Cancers (Basel). 2019 Jul 30;11(8). pii: E1078. doi: 10.3390/cancers11081078. Review.

3.

FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma.

Mahipal A, Tella SH, Kommalapati A, Anaya D, Kim R.

Cancer Treat Rev. 2019 Aug;78:1-7. doi: 10.1016/j.ctrv.2019.06.003. Epub 2019 Jun 22. Review.

PMID:
31255945
4.

Clinicopathological features and outcomes of fibrolamellar hepatocellular carcinoma.

Chakrabarti S, Tella SH, Kommalapati A, Huffman BM, Yadav S, Riaz IB, Goyal G, Mody K, Borad M, Cleary S, Smoot RL, Mahipal A.

J Gastrointest Oncol. 2019 Jun;10(3):554-561. doi: 10.21037/jgo.2019.01.35.

5.

Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma.

Huffman BM, Jin Z, Yadav S, Patel S, Nagorney DM, Truty MJ, McWilliams RR, Halfdanarson TR, Mahipal A.

Clin Colorectal Cancer. 2019 Sep;18(3):218-225. doi: 10.1016/j.clcc.2019.05.002. Epub 2019 May 15.

PMID:
31178274
6.

Survival and prognostic factors in patients with pancreatic squamous cell carcinoma.

Tella SH, Kommalapati A, Yadav S, Bergquist JR, Truty MJ, Durgin L, Ma WW, Cleary SP, McWilliams RR, Mahipal A.

Eur J Surg Oncol. 2019 Sep;45(9):1700-1705. doi: 10.1016/j.ejso.2019.05.011. Epub 2019 May 15.

PMID:
31118133
7.

First-in-human phase 1 dose-escalating trial of G305 in patients with advanced solid tumors expressing NY-ESO-1.

Mahipal A, Ejadi S, Gnjatic S, Kim-Schulze S, Lu H, Ter Meulen JH, Kenney R, Odunsi K.

Cancer Immunol Immunother. 2019 Jul;68(7):1211-1222. doi: 10.1007/s00262-019-02331-x. Epub 2019 May 8.

PMID:
31069460
8.

Local excision for patients with stage I anal canal squamous cell carcinoma can be curative.

Chakrabarti S, Jin Z, Huffman BM, Yadav S, Graham RP, Lam-Himlin DM, Lightner AL, Hallemeier CL, Mahipal A.

J Gastrointest Oncol. 2019 Apr;10(2):171-178. doi: 10.21037/jgo.2018.12.12.

9.

Solid Pseudopapillary Neoplasms of the Pancreas: A Large American Cohort.

Sanhueza CT, Huffman BM, Jin Z, Hartgers ML, Smyrk TC, Westin G, McWilliams RR, Ma WW, Alberts SR, Mahipal A.

Pancreas. 2019 Apr;48(4):e21-e22. doi: 10.1097/MPA.0000000000001288. No abstract available.

PMID:
30973464
10.

Factors Predicting Response, Perioperative Outcomes, and Survival Following Total Neoadjuvant Therapy for Borderline/Locally Advanced Pancreatic Cancer.

Truty MJ, Kendrick ML, Nagorney DM, Smoot RL, Cleary SP, Graham RP, Goenka AH, Hallemeier CL, Haddock MG, Harmsen WS, Mahipal A, McWilliams RR, Halfdanarson TR, Grothey AF.

Ann Surg. 2019 Apr 5. doi: 10.1097/SLA.0000000000003284. [Epub ahead of print]

PMID:
30946090
11.

Neoadjuvant vs. adjuvant chemotherapy for cholangiocarcinoma: A propensity score matched analysis.

Yadav S, Xie H, Bin-Riaz I, Sharma P, Durani U, Goyal G, Borah B, Borad MJ, Smoot RL, Roberts LR, Go RS, McWilliams RR, Mahipal A.

Eur J Surg Oncol. 2019 Aug;45(8):1432-1438. doi: 10.1016/j.ejso.2019.03.023. Epub 2019 Mar 21.

PMID:
30914290
12.

Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer.

Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R.

Invest New Drugs. 2019 Jun;37(3):473-481. doi: 10.1007/s10637-018-0676-8. Epub 2018 Oct 9.

PMID:
30298303
13.

Association between treatment facility volume, therapy types and overall survival in patients with intrahepatic cholangiocarcinoma.

Kommalapati A, Tella SH, Goyal G, Borad M, Alberts SR, Roberts L, Hubbard JM, Durgin L, Cleary S, Mahipal A.

HPB (Oxford). 2019 Mar;21(3):379-386. doi: 10.1016/j.hpb.2018.08.004. Epub 2018 Sep 25.

PMID:
30266490
14.

Novel immunotherapy strategies for hepatobiliary cancers.

DeLeon TT, Zhou Y, Nagalo BM, Yokoda RT, Ahn DH, Ramanathan RK, Salomao MA, Aqel BA, Mahipal A, Bekaii-Saab TS, Borad MJ.

Immunotherapy. 2018 Sep;10(12):1077-1091. doi: 10.2217/imt-2018-0024. Review.

PMID:
30185133
15.

Novel targeted treatment options for advanced cholangiocarcinoma.

Mahipal A, Kommalapati A, Tella SH, Lim A, Kim R.

Expert Opin Investig Drugs. 2018 Sep;27(9):709-720. doi: 10.1080/13543784.2018.1512581. Epub 2018 Aug 30. Review.

PMID:
30124336
16.

Survival and Prognostic Factors in Patients With Solid Pseudopapillary Neoplasms of the Pancreas.

Huffman BM, Westin G, Alsidawi S, Alberts SR, Nagorney DM, Halfdanarson TR, Mahipal A.

Pancreas. 2018 Sep;47(8):1003-1007. doi: 10.1097/MPA.0000000000001112.

PMID:
30036214
17.

Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience.

Jin Z, Hartgers ML, Sanhueza CT, Shubert CR, Alberts SR, Truty MJ, Muppa P, Nagorney DM, Smyrk TC, Hassan M, Mahipal A.

Eur J Surg Oncol. 2018 May;44(5):677-683. doi: 10.1016/j.ejso.2018.02.008. Epub 2018 Feb 16.

PMID:
29506768
18.

Contemporary Management of Localized Resectable Pancreatic Cancer.

Kommalapati A, Tella SH, Goyal G, Ma WW, Mahipal A.

Cancers (Basel). 2018 Jan 20;10(1). pii: E24. doi: 10.3390/cancers10010024. Review.

19.

Rho GTPase effectors and NAD metabolism in cancer immune suppression.

Chaker M, Minden A, Chen S, Weiss RH, Chini EN, Mahipal A, Azmi AS.

Expert Opin Ther Targets. 2018 Jan;22(1):9-17. doi: 10.1080/14728222.2018.1413091. Epub 2017 Dec 10. Review.

20.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma.

Delord JP, Robert C, Nyakas M, McArthur GA, Kudchakar R, Mahipal A, Yamada Y, Sullivan R, Arance A, Kefford RF, Carlino MS, Hidalgo M, Gomez-Roca C, Michel D, Seroutou A, Aslanis V, Caponigro G, Stuart DD, Moutouh-de Parseval L, Demuth T, Dummer R.

Clin Cancer Res. 2017 Sep 15;23(18):5339-5348. doi: 10.1158/1078-0432.CCR-16-2923. Epub 2017 Jun 13.

21.

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors.

Wagner AJ, Banerji U, Mahipal A, Somaiah N, Hirsch H, Fancourt C, Johnson-Levonas AO, Lam R, Meister AK, Russo G, Knox CD, Rose S, Hong DS.

J Clin Oncol. 2017 Apr 20;35(12):1304-1311. doi: 10.1200/JCO.2016.70.7117. Epub 2017 Feb 27.

22.

EGFR Inhibitors in Patients with Advanced Squamous Cell Anal Carcinomas: A Single-Institution Experience.

Kim DW, Byer J, Kothari N, Mahipal A, Chang YD, Kim RD.

Oncology. 2017;92(4):190-196. doi: 10.1159/000452766. Epub 2017 Feb 3.

PMID:
28152526
23.

Malignant transformation of biliary adenofibroma: a rare biliary cystic tumor.

Thompson SM, Zendejas-Mummert B, Hartgers ML, Venkatesh SK, Smyrk TC, Mahipal A, Smoot RL.

J Gastrointest Oncol. 2016 Dec;7(6):E107-E112. doi: 10.21037/jgo.2016.09.14.

24.

Role of Biologics in First-Line Treatment of Colorectal Cancer.

Mahipal A, Grothey A.

J Oncol Pract. 2016 Dec;12(12):1219-1228. Review.

PMID:
27943689
25.

Antitumor Activity of Pembrolizumab in Biomarker-Unselected Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma: Results From the Phase Ib KEYNOTE-012 Expansion Cohort.

Chow LQM, Haddad R, Gupta S, Mahipal A, Mehra R, Tahara M, Berger R, Eder JP, Burtness B, Lee SH, Keam B, Kang H, Muro K, Weiss J, Geva R, Lin CC, Chung HC, Meister A, Dolled-Filhart M, Pathiraja K, Cheng JD, Seiwert TY.

J Clin Oncol. 2016 Nov 10;34(32):3838-3845. doi: 10.1200/JCO.2016.68.1478. Epub 2016 Sep 30.

26.

Pharmacokinetics and safety of vitamin E δ-tocotrienol after single and multiple doses in healthy subjects with measurement of vitamin E metabolites.

Mahipal A, Klapman J, Vignesh S, Yang CS, Neuger A, Chen DT, Malafa MP.

Cancer Chemother Pharmacol. 2016 Jul;78(1):157-65. doi: 10.1007/s00280-016-3048-0. Epub 2016 Jun 8.

27.

Importins and exportins as therapeutic targets in cancer.

Mahipal A, Malafa M.

Pharmacol Ther. 2016 Aug;164:135-43. doi: 10.1016/j.pharmthera.2016.03.020. Epub 2016 Apr 23. Review.

PMID:
27113410
28.

Effect of Metformin Use on Survival in Resectable Pancreatic Cancer: A Single-Institution Experience and Review of the Literature.

Ambe CM, Mahipal A, Fulp J, Chen L, Malafa MP.

PLoS One. 2016 Mar 11;11(3):e0151632. doi: 10.1371/journal.pone.0151632. eCollection 2016.

29.

First-in-Class, First-in-Human Phase I Study of Selinexor, a Selective Inhibitor of Nuclear Export, in Patients With Advanced Solid Tumors.

Abdul Razak AR, Mau-Soerensen M, Gabrail NY, Gerecitano JF, Shields AF, Unger TJ, Saint-Martin JR, Carlson R, Landesman Y, McCauley D, Rashal T, Lassen U, Kim R, Stayner LA, Mirza MR, Kauffman M, Shacham S, Mahipal A.

J Clin Oncol. 2016 Dec;34(34):4142-4150. Epub 2016 Oct 31.

30.

Use of Radiation Therapy in Locally Advanced Pancreatic Cancer Improves Survival: A SEER Database Analysis.

Sajjad M, Batra S, Hoffe S, Kim R, Springett G, Mahipal A.

Am J Clin Oncol. 2018 Mar;41(3):236-241. doi: 10.1097/COC.0000000000000261.

PMID:
26796313
31.

Clinical Outcomes of Patients With Gastrointestinal Malignancies Participating in Phase I Clinical Trials.

Denson A, Burke N, Wapinsky G, Bertels B, Juan TH, Lee J, Springett GM, Strosberg JR, Kim RD, Sullivan DM, Mahipal A.

Am J Clin Oncol. 2018 Feb;41(2):133-139. doi: 10.1097/COC.0000000000000242.

32.

Management of borderline resectable pancreatic cancer.

Mahipal A, Frakes J, Hoffe S, Kim R.

World J Gastrointest Oncol. 2015 Oct 15;7(10):241-9. doi: 10.4251/wjgo.v7.i10.241. Review.

33.

Second-Line Treatment of Advanced Gastric Cancer: Where Do We Stand?

Mahipal A, Choi M, Kim R.

J Natl Compr Canc Netw. 2015 Oct;13(10):1281-91; quiz 1292. Review.

PMID:
26483065
34.

Phase I trial of combination of FOLFIRI and pasireotide, a somatostatin analogue, in advanced gastrointestinal malignancies.

Mahipal A, Shibata D, Siegel E, Springett G, Almhanna K, Fulp W, Williams-Elson I, Kim R.

Invest New Drugs. 2015 Oct;33(5):1093-9. doi: 10.1007/s10637-015-0277-8. Epub 2015 Aug 16.

PMID:
26275531
35.

Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.

Suleiman Y, Mahipal A, Shibata D, Siegel EM, Jump H, Fulp WJ, Springett GM, Kim R.

Cancer Chemother Pharmacol. 2015 Sep;76(3):481-7. doi: 10.1007/s00280-015-2814-8. Epub 2015 Jul 1.

PMID:
26126727
36.

Effect of Age on Clinical Outcomes in Phase 1 Trial Participants.

Mahipal A, Denson AC, Djulbegovic B, Lush R, Kumar A, Juan TH, Schell MJ, Sullivan DM.

Cancer Control. 2015 Apr;22(2):235-41.

PMID:
26068771
37.

PET/CT Fusion Scan Prevents Futile Laparotomy in Early Stage Pancreatic Cancer.

Kim R, Prithviraj G, Kothari N, Springett G, Malafa M, Hodul P, Kim J, Yue B, Morse B, Mahipal A.

Clin Nucl Med. 2015 Nov;40(11):e501-5. doi: 10.1097/RLU.0000000000000837.

38.

A Meta-analysis of Randomized Clinical Trials of Chemoradiation Therapy in Locally Advanced Pancreatic Cancer.

Ambe C, Fulp W, Springett G, Hoffe S, Mahipal A.

J Gastrointest Cancer. 2015 Sep;46(3):284-90. doi: 10.1007/s12029-015-9734-z. Review.

PMID:
26018826
39.

Selective Nuclear Export Inhibitor KPT-330 Enhances the Antitumor Activity of Gemcitabine in Human Pancreatic Cancer.

Kazim S, Malafa MP, Coppola D, Husain K, Zibadi S, Kashyap T, Crochiere M, Landesman Y, Rashal T, Sullivan DM, Mahipal A.

Mol Cancer Ther. 2015 Jul;14(7):1570-81. doi: 10.1158/1535-7163.MCT-15-0104. Epub 2015 May 1.

40.

Paradoxical effect of capecitabine in 5-fluorouracil-induced cardiotoxicity: A case vignette and literature review.

Saneeymehri SS, Markey KR, Mahipal A.

J Oncol Pharm Pract. 2016 Jun;22(3):552-5. doi: 10.1177/1078155215579303. Epub 2015 Apr 6. Review.

PMID:
25852107
41.

Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody® targeting the DR5 receptor.

Papadopoulos KP, Isaacs R, Bilic S, Kentsch K, Huet HA, Hofmann M, Rasco D, Kundamal N, Tang Z, Cooksey J, Mahipal A.

Cancer Chemother Pharmacol. 2015 May;75(5):887-95. doi: 10.1007/s00280-015-2712-0. Epub 2015 Feb 27.

PMID:
25721064
42.

Carboplatin and paclitaxel treatment is effective in advanced anal cancer.

Kim R, Byer J, Fulp WJ, Mahipal A, Dinwoodie W, Shibata D.

Oncology. 2014;87(2):125-32. doi: 10.1159/000361051. Epub 2014 Jul 8.

PMID:
25012155
43.

Participation of the elderly population in clinical trials: barriers and solutions.

Denson AC, Mahipal A.

Cancer Control. 2014 Jul;21(3):209-14. Review.

PMID:
24955704
44.

Risks and benefits of phase 1 clinical trial participation.

Mahipal A, Nguyen D.

Cancer Control. 2014 Jul;21(3):193-9. Review.

PMID:
24955702
45.

Clinical trials and drug development.

Mahipal A.

Cancer Control. 2014 Jul;21(3):188-9. No abstract available.

PMID:
24955701
46.

Epidermal growth factor receptor inhibitors: coming of age.

Mahipal A, Kothari N, Gupta S.

Cancer Control. 2014 Jan;21(1):74-9. Review.

PMID:
24357745
47.

Biomarkers for pancreatic cancer: is it ready for primetime?

Kim R, Mahipal A, Choi M, Saif MW.

JOP. 2013 Jul 10;14(4):309-11. doi: 10.6092/1590-8577/1676. No abstract available.

48.

Role of systemic chemotherapy in urothelial urinary bladder cancer.

Gupta S, Mahipal A.

Cancer Control. 2013 Jul;20(3):200-10. Review.

PMID:
23811704
49.

A pilot study of sunitinib malate in patients with metastatic uveal melanoma.

Mahipal A, Tijani L, Chan K, Laudadio M, Mastrangelo MJ, Sato T.

Melanoma Res. 2012 Dec;22(6):440-6. doi: 10.1097/CMR.0b013e328358b373.

PMID:
23114504
50.

Small-cell carcinoma of the gallbladder: report of a case and literature review.

Mahipal A, Gupta S.

Gastrointest Cancer Res. 2011 Jul;4(4):135-6. No abstract available.

Supplemental Content

Loading ...
Support Center